PTAB Weighs Sanofi Insulin Pen Patents In Mylan IP Row

Law360 (January 15, 2020, 10:16 PM EST) -- The Patent Trial and Appeal Board asked tough questions about the role of injection force during six consolidated inter partes reviews Wednesday in Mylan’s effort to knock out several Sanofi-Aventis patents covering the Lantus SoloStar disposable insulin injection pen.

Mylan Pharmaceuticals Inc. argued that the Sanofi patents would have been obvious to a skilled artisan — someone with a bachelor’s degree in mechanical engineering with an understanding of medical device design — and said Sanofi hung its validity defense on an element the patents don’t even claim.

Mylan said a skilled artisan would have been motivated to undertake various modifications of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS